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CONSENSUS
Statement

Consensus guidelines for management
of hyperammonaemia in paediatric
patients receiving continuous kidney
replacement therapy
Rupesh Raina1,2,21 ✉, Jirair K. Bedoyan3,21, Uta Lichter-Konecki4, Philippe Jouvet5,
Stefano Picca6, Nicholas Ah Mew7, Marcel C. Machado8, Ronith Chakraborty2,
Meghana Vemuganti9, Manpreet K. Grewal10, Timothy Bunchman11, Sidharth Kumar Sethi12,
Vinod Krishnappa2,13, Mignon McCulloch14, Khalid Alhasan15, Arvind Bagga16,
Rajit K. Basu17, Franz Schaefer18, Guido Filler 19 and Bradley A. Warady20

Abstract | Hyperammonaemia in children can lead to grave consequences in the form of cerebral
oedema, severe neurological impairment and even death. In infants and children, common
causes of hyperammonaemia include urea cycle disorders or organic acidaemias. Few studies
have assessed the role of extracorporeal therapies in the management of hyperammonaemia
in neonates and children. Moreover, consensus guidelines are lacking for the use of non-kidney
replacement therapy (NKRT) and kidney replacement therapies (KRTs, including peritoneal
dialysis, continuous KRT, haemodialysis and hybrid therapy) to manage hyperammonaemia in
neonates and children. Prompt treatment with KRT and/or NKRT, the choice of which depends
on the ammonia concentrations and presenting symptoms of the patient, is crucial. This expert
Consensus Statement presents recommendations for the management of hyperammonaemia
requiring KRT in paediatric populations. Additional studies are required to strengthen these
recommendations.
In aqueous solution, ammonia exists as ammonium
hydroxide ions, which aid in maintaining acid–base
homeostasis1,2, as expressed by the following equilibrium:

NH 3 + H 2O ⇄ (NH 4 +) + (OH −)

✉e-mail: rraina@
akronchildrens.org
https://doi.org/10.1038/
s41581-020-0267-8

Hyperammonaemia is the excessive accumulation of
ammonia in the blood, which can result in moderate to
severe neurological impairment and cerebral oedema.
Ammonia is produced by amino acid catabolism, the
activity of glutamine dehydrogenase in the liver, kidney,
pancreas and brain, and by the deamination of AMP
during exercise in skeletal muscle1. Most ammonia pro
duced enters the urea cycle in hepatocytes, is excreted
in the urine as urea or is converted into glutamine, a
fraction of which is also excreted by the kidneys1,3.
Typically, blood ammonia concentrations ≤35 µmol/l
(<60 µg/dl) are considered normal, whereas high
concentrations can produce toxic effects and levels
>200 µmol/l (341 µg/dl) are associated with poor neuro
logical outcomes2. The primary differential diagnosis
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of hyperammonaemia in infants and children relates to
inborn errors of metabolism, including urea cycle dis
orders (UCDs) and organic acidaemias2. Toxic levels of
ammonia can be due to either a primary or a secondary
deficiency of the urea cycle. Congenital deficiency of any
of the six enzymes within this cycle — N-acetylglutamate
synthase (NAGS), carbamoyl phosphate synthase I
(CPS), ornithine transcarbamylase (OTC), arginino
succinate synthetase (ASS), argininosuccinate lyase
(ASL) and arginase 1 — will result in a build-up of both
ammonia and the substrate of the specific enzyme4.
UCDs occur in ~1 in 35,000 births, among which OTC
deficiency is the most common, with an incidence of 1
in 56,500 births4. Hyperammonaemia due to secondary
inhibition of the urea cycle occurs in the context of other
congenital metabolic abnormalities (such as organic
acidaemias), following exposure to certain drugs (such as
valproic acid) and in various liver diseases. Organic acid
aemias, including methylmalonic acidaemia, propionic
acidaemia, isovaleric acidaemia and multiple carboxylase
deficiency occur in ~1 in 21,000 births and typically lead
volume 16 | August 2020 | 471
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to mild to moderate hyperammonaemia due to com
petitive inhibition of NAGS5–9. Paediatric patients with
acute liver or kidney injury are also susceptible to an
accumulation of ammonia due to impaired metabolism
and excretion processes, respectively2 (Fig. 1).
Hyperammonaemia is defined as >100 µmol/l
(170 µg/dl) in neonates or ≥50 µmol/l (85 µg/dl) in term
infants, children and adolescents10. Individual labora
tory reference intervals vary and some age dependency
of ammonia levels is evident (that is, levels are higher
in premature neonates). Early onset hyperammonaemia
presents in neonates within the first few days of life after
they start to feed and can no longer rely on maternal
(placental) transport to appropriately eliminate the accu
mulating ammonia2,4,7. Symptoms in preterm neonates
typically result from transient hyperammonaemia of
the newborn, which is characterized by the absence
of organic acidurias and normal activity of urea cycle
enzymes. This subtype is usually associated with complete
recovery, usually without needing treatment.
In hyperammonaemia, the acute rise in ammonia
levels in the brain leads to increased levels of extracellu
lar potassium and metabolism of ammonia to glutamine
by astrocytes1,3,11. These changes result in increased
intracellular osmolality, cerebral oedema and the release
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of inflammatory cytokines. High levels of extracellular
potassium and glutamate released by astrocytes lead
to neuronal damage1,3. Elevated levels of glutamine,
which is the end product of ammonia detoxification,
is a key factor in both hepatic encephalopathy and
ammonia-related neurotoxicity12. Apart from hyperam
monaemia, adverse effects on the nitric oxide pathway
are also thought to lead to brain damage in patients with
UCDs13. The clinical abnormalities observed vary for
each specific UCD, but most patients tend to have simi
lar symptoms14. The clinical features of an acute hyper
ammonaemic episode depend on the age of the patient
and the cause of the elevation in plasma ammonia levels.
Early symptoms include lethargy, loss of appetite and
vomiting. As ammonia levels rise, symptoms can pro
gress to hyperventilation resulting in respiratory alka
losis, hypotonia, ataxia, disorientation, seizures and,
if untreated, coma and death15. Late-onset hyperam
monaemia in children, adolescents or adults can result
from a partial or mild deficiency in a urea cycle enzyme
that is exacerbated by certain stressors. Such children
or adolescents present with failure to thrive, irritability,
seizures, vomiting, ataxia and intellectual disabilities.
Management of hyperammonaemia is challenging in
paediatric populations given the non-specific clinical
symptoms, the age-specific aetiologies and the lack of
consensus in the treatment plan. Historically, the prog
nosis in neonates with hyperammonaemia was poor, but
current treatments, along with prompt identification
of hyperammonaemia, have considerably improved
the survival of affected neonates16 (Fig. 2), although
updated survival data are not available.
This Consensus Statement presents guidelines for
non-kidney replacement therapy (NKRT) and kidney
replacement therapy (KRT) of hyperammonaemia in
paediatric patients. KRT includes peritoneal dialy
sis (PD), haemodialysis (HD) and continuous kidney
replacement therapy (CKRT). Varieties of CKRT include
continuous venovenous haemofiltration (CVVH), con
tinuous venovenous haemodiafiltration (CVVHDF)
and hybrid therapy. These guidelines and the included
recommendations will be reviewed every 2 years.

Methods
The PCRRT workgroup. The PCRRT workgroup com
prises an international expert panel of paediatric nephro
logists from various professional societies representing
a diverse paediatric population. The workgroup chair
was T.B. (paediatric nephrologist, chair and founder of
PCRRT). Co-chairs were J.K.B. (clinical and biochemi
cal geneticist, Department of Genetics and Genome
Sciences, Associate Director of the Center for Human
Genetics (Metabolism Section) and Section Medical
Director, CIDEM Laboratory, University Hospitals
Cleveland Medical Center) and R.R. (adult and paediatric
nephrologist). The workgroup guidelines were discussed
with international panellists at the Pediatric Critical Care
Nephrology & Renal Replacement Therapy workshop
(sponsored by PCRRT) on 11 April 2019. These experts
met to discuss and develop recommendations for the
management of paediatric hyperammonaemia with KRT.
Further meetings were held at a consensus conference
www.nature.com/nrneph
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Fig. 1 | Urea cycle dysfunction results in toxic accumulation of ammonia in the blood. Hyperammonaemia in neonates
and infants is typically caused by inborn errors of metabolism. Primary urea cycle disorders are caused by congenital
deficiency of any of the six urea cycle enzymes: N-acetylglutamate synthase (NAGS), carbamoyl phosphate synthase I
(CPS1), ornithine transcarbamylase (OTC), argininosuccinate synthetase (ASS), argininosuccinate lyase (ASL) and arginase 1
(ARG1). These deficiencies result in severe hyperammonaemia and the accumulation of both urea and the substrate of the
missing or defective enzyme. For example, the accumulation of carbamoyl phosphate (CP; dashed line) results in greatly
increased production and excretion of orotate. Secondary inhibition of the urea cycle is caused by abnormalities that
reduce the activity of other enzymes involved in amino acid processing. These deficiencies cause organic acidaemias, such
as methylmalonic acidaemia, propionic acidaemia, isovaleric acidaemia and multiple carboxylase deficiency, as well as
(typically mild to moderate) hyperammonaemia. Hyperammonaemia can also occur following exposure to drugs, such as
valproic acid. Finally, paediatric patients with liver diseases or acute kidney injury are also susceptible to hyperammonaemia
owing to impaired metabolism or excretion of urea, respectively68. αKG, α-ketoglutarate; AGC, aspartate–glutamate carrier;
GDH, glutamate dehydrogenase; GLNase, glutaminase; GLN-Tx, glutamine transporter; GS, glutamine synthase;
NAG, N-acetylglutamate; NOS, nitric oxide synthase; NO, nitric oxide; ORNT1, ornithine translocase.

during the International Society of Nephrology (ISN)
biennial World Congress of Nephrology in Melbourne,
Australia, 12–15 April 2019. The workgroup members all
disclosed any conflicts of interest, and all participated in
a careful review of the objectives, background, rationale
and statistical methods used in this study.
The literature search, article review, data extraction
and results were completed by the PCRRT co-chairs,
who submitted their results to the workgroup for dis
cussion. All individuals were responsible for reviewing
and proposing recommendations for KRT in children
with hyperammonaemia. Disagreements between
panel members were resolved by quantifying votes
using the RAND Corporation/University of California
Los Angeles (UCLA) appropriateness method and
subsequently calculating a disagreement index17,18.
NAtuRe RevIeWs | NEPHRology

The modified Delphi method was used to establish the
strength of each recommendation. Grading of recom
mendations, assessments, development, and evaluation
(GRADE) criteria19 were used to establish the evidence
level for each clinical recommendation.
Data selection and review. The PubMed/MEDLINE,
EMBASE and Cochrane databases were searched to
identify publications relevant to hyperammonaemia and
KRT in the paediatric population. Medical subject head
ings (MeSH terms) used in the creation of the search
strategy included “renal replacement therapy”, “renal
dialysis*”, “kidney replacement”, “hemofiltration*”,
“hemodialysis”, “dialysis”, “peritoneal dialysis”, “CAPD”,
“hemodiafiltration*”, “hemoperfusion*” and “hyperam
monemia*”. Asterisks denote terms that were expanded
volume 16 | August 2020 | 473

C o n S e n S u S S tat e m e n t
b Infants, children and adults
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Fig. 2 | Clinical manifestations of hyperammonaemia. The clinical features of an acute hyperammonaemic episode are
influenced by the age of the patient and the underlying cause of hyperammonaemia — that is, the specific urea cycle
enzyme deficiency or organic acidaemia. a | In neonates, early symptoms include lethargy, loss of appetite and vomiting.
If ammonia levels continue to rise, symptoms progress to hypotonia and hyperventilation resulting in respiratory alkalosis.
Severe hyperammonaemia is characterized by an acute encephalopathy, seizures, and, if untreated, coma and death.
b | Late-onset hyperammonaemia (that is, in infants, children and adults) typically results from a partial or mild urea cycle
enzyme deficiency exacerbated by exposure to stressors such as drug treatment. These individuals typically present
with failure to thrive and abdominal symptoms, accompanied by psychiatric manifestations such as irritability, learning
disabilities, delusion and psychosis. Patients might additionally have neurological symptoms, including neurodevelopmental
delay, seizures and hemiplegia. The psychiatric and neurological manifestations of hyperammonaemia are attributable to
increased brain levels of ammonia, which is metabolized to glutamine by astrocytes. The resulting high extracellular levels
of potassium and glutamine cause increased intracellular osmolality and cerebral oedema, leading to neuronal damage and
the release of inflammatory cytokines.

to search all related terms on the familial hierarchy. The
MeSH term “hyperammonemia” included narrower
terms such as “urea cycle disorder”, “hyperlysinemia”,
“hyperornithinemia”, “hyperammonemia and homocit
rullinuria (HHH) syndrome”, “methylmalonic aciduria”,
“CPS deficiency disease”, “OTC deficiency disease” and
“propionic aciduria”. The search strategy was limited to
patients aged 0–18 years. Supplementary Box 1 lists the
full and specific search strategies used.
The initial database searches returned a total of 477
citations. All citations obtained were reviewed by two
independent reviewers. A PICO (patient, problem or
population; intervention; comparison, control or com
parator; outcomes) model table was constructed to
illustrate the inclusion and exclusion criteria (Table 1).
Each title, abstract and full-text article was assessed by
two independent reviewers. To settle disputes and assess
inter-rater agreements, a third independent reviewer
also assessed the articles. After removal of duplicates,
329 citations remained, of which 118 were considered
for full-text review. Supplementary Table 1 shows the
474 | August 2020 | volume 16

PRISMA statement checklist that was used in report
ing the selected articles20. The Cochrane risk of bias
assessment tool for randomized control trials and the
Newcastle–Ottawa scales for cohort studies were used
to assess the quality of the included studies21,22.
The workgroup considered data from 28 of these
studies to be most relevant for formulating the guide
lines. A total of 172 patients were included in these
28 studies, with ages ranging from 1 day to 7 years.
Hyperammonaemia was associated with a multi
tude of aetiologies, the most common of which were
inborn errors of metabolism. The most frequent inborn
errors of metabolism were CPS deficiency (n = 16),
propionic acidaemia (n = 15) and methylmalonic aci
daemia (n = 13). Indications for HD included hyper
ammonaemia refractory to medical management and
hyperammonaemic coma. Illness severity ranged from
haemodynamically stable to hyperammonaemic coma.
Dialysis duration ranged from 2 h to 19 days. The success
rates for each modality were 65% for PD (n = 23), 100%
for intermittent HD (n = 5), 60% for CKRT (n = 92),
www.nature.com/nrneph
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and 100% for extracorporeal membrane oxygenation
(ECMO) combined with CKRT (n = 18). Criteria for suc
cess consisted of a decrease in ammonia to normal lev
els and a good clinical outcome with minimal rebound
hyperammonaemia. The most pertinent data on patient
characteristics, HD parameters and outcomes are sum
marized in Table 2 (an expanded table is provided as
Supplementary Table 2).
In the literature review, very few randomized con
trolled trials and meta-analyses were identified, and
those identified were excluded from the scope of the
present expert Consensus Statement on the basis of
insufficient quality and a lack of pertinent information.
All the recommendations were made on the basis of
case reports and retrospective studies (Table 3). Clearly,
high grades of evidence19 could not be provided based
on case reports and retrospective studies describing a
few, rare and scattered paediatric patients with hyper
ammonaemia requiring dialysis. Yet, guidelines with
low evidence grading can still be of immense value to
clinicians while waiting for additional evidence. Another
limitation of the study concerns the lack of consensus
on the preferred modality for KRT, the type of dialyser,
membrane and filtration rate; these parameters were
all institution-dependent and thus not generalizable.
Indications for KRT were also variable; some stud
ies initiated KRT at a certain ammonia level (typically
>400 μmol/l (681 μg/dl)), whereas others initiated KRT
when the patient was haemodynamically unstable, irre
spective of the patient’s ammonia level. Future large-scale
studies are necessary to establish more specific guidelines
for KRT in paediatric patients with hyperammonaemia.

Consensus panel recommendations
Prompt identification and treatment of hyperam
monaemia are imperative to optimize the outcome of a
hyperammonaemic crisis and to avoid irreversible brain
damage.
Initial medical management guidelines. In the ini
tial medical management of acute hyperammonae
mia, the patient should be immediately stabilized
(circulation, airway and breathing), vital signs should
be addressed, blood glucose levels monitored, intra
venous access should be established, airways should
be maintained by intubation and ventilation if nec
essary, and adequate rehydration should be started,
typically using a dextrose-containing fluid at a high
infusion rate 23. In patients in hypera mmonaemic
crisis, laboratory testing is required to establish the
cause of hyperammonaemia24. Accurate measurement
Table 1 | Study eligibility criteria
Category

Inclusion criteria

Exclusion criteria

Population

Adult patients
Paediatric patients (aged 0–18 years)
who received non-kidney replacement (aged >18 years)
therapy or kidney replacement therapy

Outcomes analysed Hyperammonaemia

NA

Study type

Meta-analyses, systemic
reviews, abstracts

Case reports, retrospective studies

NA , not applicable
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of plasma levels of ammonia is also important and
should be performed on a free-f lowing venous
or arterial blood sample collected into a lithium heparin or
EDTA tube and transported on ice to the laboratory. The
sample must be processed within 15 min of draw and
analysed immediately.
Once hyperammonaemia is identified, protein intake
must be temporarily stopped and plasma ammonia
levels monitored every 3 h (ref.10). In a patient with an
ammonia level at the upper limit of normal for their
age — that is, 110 μmol/l (154 μg/dl) at age 1–7 days,
<90 μmol/l (126 μg/dl) at age 8–14 days and 16–53 µmol/l
(22–74 μg/dl) at age 15 days to adult — stopping pro
tein intake and initiating intravenous glucose and
lipids to prevent catabolism is generally adequate.
Crucially, protein intake must be reintroduced within
a maximum of 48 h following the return of ammonia
levels to 80–100 μmol/l (136–170 μg/dl) in order to avoid
catabolism23. Two factors determine the prognosis of
neurological damage: the duration of hyperammonae
mic coma and plasma ammonia levels25,26. Adverse
prognostic factors include hyperammonaemic coma
lasting >3 days, increased intracranial pressure and/or a
plasma ammonia level >1,000 μmol/l (1,703 μg/dl)15. In
a study of 22 children with UCDs who survived a hyper
ammonaemic coma, the duration of coma was inversely
correlated with the children’s IQ at 12 months after
recovery from the hyperammonaemic coma27,28. The
severity of abnormalities on brain CT also correlated
with the duration of coma29. Early management and
reduced duration of hyperammonaemic coma may pre
vent adverse neurological outcomes29. The initial medi
cal and nutritional management of hyperammonaemia
is summarized in Box 1.
NKRT guidelines. NKRT is generally indicated at serum
ammonia levels >150 μmol/l (255 μg/dl). The goal
of NKRT is to provide an alternative route for nitro
gen excretion (that is, its sequestration by nitrogen-
scavenging agents) 2. Nitrogen scavengers include
sodium benzoate, sodium phenylacetate, sodium phenyl
butyrate (a precursor of phenylacetate) and glycerol
phenylbutyrate. Benzoate conjugates with glycine to
generate hippurate, whereas phenylacetate conjugates
with glutamine to generate phenylacetylglutamine23,30.
Intravenous sodium benzoate and sodium phenyl
acetate can often be administered much more rapidly
than KRT. These agents can also be administered in con
junction with KRT but will be dialysed along with other
small molecules. Nonetheless, in one infant with hyper
ammonaemia due to a suspected inborn error of meta
bolism, the use of a cocktail of intravenous nitrogen
scavengers followed by sequential HD and haemofil
tration successfully corrected the hyperammonaemia
despite rapid clearance of the nitrogen scavengers by
dialysis31.
Additionally, urea cycle intermediates such as
l-arginine or l-citrulline are primers of the urea cycle
that can be supplemented to aid in ammonia removal.
The choice of intermediate depends on which deficiency
is present. l-Arginine is also a precursor to nitric oxide,
a potent vasodilator; intravenous administration of
volume 16 | August 2020 | 475
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Table 2 | Summary of data from the most important included studies
Study population

KRT duration

Ammonia levels (clearance)

Ref.

9 patients, mean age 11.7 ( ± 9.7) days, with MSUD
(n = 3), hyperammonaemia and/or organic acidaemias
(n = 4) or UCDs (n = 2)

4.6 ± 1.9 days

Pre-KRT peak range 531–1,533 μmol/l
(904.35–2,610.85 μg/dl); post-KRT 300 ± 440 μmol/l
(510.93 ± 749.36 μg/dl) (66%)

37

7 patients, mean age 2–3 days, with CPS deficiency
(n = 1), PA (n = 3), MMA (n = 1), OTC deficiency (n = 1)
or ASL (n = 1)

Mean 2.4 days (range 5 h
to 15 days)

Pre-KRT >1,000 μmol/dl (1,703.1 μg/dl); 20 h after KRT
<200 mg/dl (340.62 μg/dl) (57%)

56

1 patient aged 2 days with citrullinaemia

2 rounds: 4.5 h and 2 h

Pre-KRT peak 874 μmol/l (1,488.51 μg/dl); post-KRT
588 μmol/l (1,001.42 μg/dl), then 89 μmol/l (151.58 μg/dl)
(100%)

48

4 patients aged 7 h to 10 days with transient
hyperammonaemia (n = 2), MMA (n = 1) or OTC
deficiency (n = 1)

Mean 4–5 h; 2 patients
required multiple
sessions

Pre-KRT average 595 μmol/l (1,013.34 μg/dl); post-KRT
180 μmol/l (306.56 μg/dl) (100%)

46

1 patient aged 2 years with CPS deficiency

Mean 14 h

Pre-KRT peak hyperammonaemia 765 μmol/l
(1,302.87 μg/dl); post-KRT 153 μmol/l (260.57 μg/dl)
(100%)

57

1 patient aged 3 days with MMA

2 h HD then 14 h HF

Pre-KRT peak hyperammonaemia 1,533 μmol/l
(2,610.85 μg/dl); post-KRT 209 μmol/l (292.76 μg/dl)
(100%)

31

14 patients, mean age 5.5 ± 7.4 months, with OTC
deficiency (n = 5), MSUD (n = 4) or CPS deficiency (n = 5)

CVVHDF (n = 11) or
CVVHD (n = 3) mean
16.6 ± 15.6 h

(n = 10) Post-KRT <200 μmol/l (340.62 μg/dl) (86.70%)

58

21 patients, mean age 4.1 ± 2.4 days (n = 19), 1 year
(n = 1), 7 years (n = 1), with citrullinaemia (n = 8), OTC
deficiency (n = 3), MMA (n = 2), CPS deficiency (n = 3),
PA (n = 1), glutaric acidaemia type II (n = 1), argininaemia
(n = 1), unknown diagnosis (n = 2)

CVVHD mean 42 ± 30.4 h
(n = 17); PD mean
59.4 ± 87.2 h (n = 4)

Pre-KRT peak hyperammonaemia
1,225.8 ± 1,172.9 μmol/l (1,717 ± 1,643 μg/dl); 50%
reduction within 4.7 ± 2.5 h for CVVHD (84%) and within
13.5 ± 6.2 h for PD (50%)

59

3 patients aged 3–7 days with MMA

CAVHDF mean 19 h

Pre-KRT peak hyperammonaemia 449–932 μg/dl;
post-KRT 85–124 μg/dl (100%)

60

21 patients aged 15.7 ± 11.7 days with anuria and
hyperhydration (n = 17), azotaemia with anuria (n = 1),
HUS (n = 1) or neonatal hyperammonaemia (n = 2)

CVVH (n = 12); CVVHD
(n = 1); CAVHF (n = 1);
CVVHDF (n = 6); mean
66.8 ± 56.6 h

Pre-KRT peak >1,300 μmol/l (2,214.03 μg/dl); post KRT
347 μmol/l (590.98 μg/dl) with CVVHD; 104 μmol/l
(177.12 μg/dl) with CVVHDF (42.90%)

61

4 patients aged 2–3 days with CPS deficiency (n = 1),
MMA (n = 1) or pyruvate carboxylase deficiency (n = 2)

CVVHDF mean 30 h

Pre-KRT 152.66–1,051.02 μmol/l (260–1,790 μg/dl;
post-KRT <117.43 μmol/l (200 μg/dl) (50%)

39

12 patients aged 4 days to 2 months with MSUD (n = 4),
PA (n = 3), CPS deficiency (n = 2), CPS deficiency (n = 2),
ASL deficiency (n = 1)

CVVHD mean 29.5 h
(n = 7), PD dwell time
30–60 min; mean 73 h
(n = 5)

Pre-KRT peak 3,820 μmol/l (6,505.84 μg/dl); 50%
ammonia reduction time 7.1 h for CVVHD and 17.9 h
for PD (83%)

38

21 patients aged 56.2 ± 71.0 months with UCDs
(n = 14), organic acidaemias (n = 5), idiopathic
hyperammonaemia (n = 1) or Reye syndrome (n = 1)

HD then CVVHD mean
6.1 ± 9.8 days

Pre-KRT 721.4 ± 467.2 μmol/l (1,010.5 ± 654.4 μg/dl);
post-KRT <200 μmol/l (340.62 μg/dl) (100%)

49

2 patients aged 5 days with PA

CVVHD with HF–ECMO;
70–80 ml/h, 40–90 ml/h;
33 h

Pre-KRT >968 μmol/l (1,355.90 μg/dl); post-KRT
102 μmol/l (142.9 μg/dl) (100%)

50

2 patients aged 5 days and 4 days with ASL deficiency
(n = 10 or UCD (n = 1)

HD–ECMO 2 h

Pre-KRT 780 μmol/l (1,328.42 μg/dl), 1,500 μmol/l
(2,554.65 μg/dl); post-KRT 24 μmol/l (40.88 μg/dl),
35 μmol/l (59.61 μg/dl), respectively (100%)

51

Pre-KRT peak 1,041 μmol/l (1,772.93 μg/dl); post-KRT
<200 μmol/l (280.1 μg/dl) (100%)

52

Peritoneal dialysis

Haemodialysis

Continuous kidney replacement therapy

Hybrid therapy

13 patients, mean age 38.1 weeks (IQR 37.0–39.0 weeks), HD–ECMO 7.3 h
with deficiency of ASL (n = 6), CPS (n = 5), OTC (n = 2),
(IQR 3.6–13.5 h)
isovaleric acid CoA dehydrogenase (n = 1) propionyl
CoA carboxylase (n = 1) or organic acidaemia (n = 2)

Expanded information on the included studies is available online in Supplementary Table 2 (refs31,37–39,46,48–53,56–67). ASL , argininosuccinate lyase; CAVHDF, continuous
arteriovenous haemodiafiltration; CAVHF, continuous arteriovenous haemofiltration; CoA , coenzyme A; CPS, carbamoyl phosphate synthetase; CVVH, continuous
venovenous haemofiltration; CVVHD, continuous venovenous haemodialysis; CVVHDF, continuous venovenous haemodiafiltration; ECMO, extracorporeal
membrane oxygenation; HD, haemodialysis; HF, haemofiltration; HUS, haemolytic uraemic syndrome; IQR , interquartile range; KRT, kidney replacement therapy;
MMA , methyl malonic acidaemia; MSUD, maple syrup urine disease; OTC, ornithine transcarbamylase; PA , propionic acidaemia; PD, peritoneal dialysis;
UCD, urea cycle disorders.
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Table 3 | Dialysis ammonia clearance and filtration fractions
Number of
patients

Dialysis
modality

Qb (ml/min)

Qd (ml/min)

Ammonia clearance
(ml/min/kg body weight)

Ammonia filtration
fraction (%)

3

CAVHD

10–20

8.3 (0.5 l/h)

0.87–0.97

12.5–14.3

3

CVVHD

20–40

33.3–83.3 (2–5 l/h)

2.65–6.80

53.0–58.0

2

HD

10–15

500

3.95–5.37

95.0–96.0

CAVHD, continuous arteriovenous haemodialysis; CVVHD, continuous venovenous haemodialysis; HD, haemodialysis; Qb, blood
flow rate; Qd, dialysis fluid flow rate. Based on data from ref.34.

arginine could therefore lead to hypotension. The argi
nine dose might need to be titrated or reduced, espe
cially if the patient is simultaneously receiving HD. In
patients with ammonia levels >150 μmol/l (255 μg/dl),
the protocol depends on the blood ammonia level and
whether or not the patient has a known UCD. Treatment
of hyperammonaemia based on the ammonia level in
both undiagnosed patients and patients with known
UCDs should be initiated according to the guidelines
for NKRT management23,30. Box 2 presents the consensus
panel’s recommendations for NKRT.
KRT guidelines. Ammonia is amenable to diffusive
dialysis as it does not notably bind to albumin or other
proteins and is a small molecule with a molecular weight
of 17 Da2. Published indications for dialysis in neonates
and children include serum ammonia level >500 μmol/l
(852 μg/dl) or a lower level if there is an inadequate
clinical response after 4 h of medical management10,32.
If serum levels of ammonia are 100–300 μmol/l
(170–511 μg/dl) and the patient shows clinical signs of
Box 1 | Medical management of hyperammonaemia30
Stop protein intake.
• i.v. glucose: infusion rate 8–10 mg/kg/min
• i.v. lipids: 0.5 g/kg daily, up to 3 g/kg daily
• Caloric intake: ≥100 kcal/kg daily
• i.v. sodium benzoate: maximum 12 g daily (high-dose benzoate can be toxic and lethal
within 1 h) given over 90 min as bolus then as maintenance over 24 h:
-- weight <20 kg, 250 mg/kg
-- weight >20 kg, 5.5 g/m2
• i.v. sodium phenylacetate, given over 90 min as bolus then as maintenance over 24 h:
-- weight <20 kg, 250 mg/kg
-- weight >20 kg, 5.5 g/m2
• i.v. sodium benzoate and sodium phenylacetate, given over 90–120 min as bolus then
as maintenance over 24 h:
-- weight <20 kg, 250 mg/kg
-- weight >20 kg, 5.5 g/m2
• i.v. l-arginine hydrochloride, given over 90 min as bolus then as maintenance over 24 h:
-- weight <20 kg; 200 mg/kg in patients with OTC and CPS deficiencies, 600 mg/kg in
patients with ASS and ASL deficiencies
-- weight >20 kg; 4 g/m2 in patients with OTC and CPS deficiencies, 12 g/m2 in patients
with ASS and ASL deficiencies
• i.v. l-carnitine: 50 mg/kg loading dose given over 90 min, then 100–300 mg/kg daily
(not needed in patients with UCDs but needed in patients with organic acidaemias)
• Vitamins (B12 1 mg, biotin 5–15 mg)
• Oral phenylbutyrate (after UCD diagnosis)
ASL, argininosuccinate lyase; ASS, argininosuccinate synthase; CPS, carbamoyl phosphate
synthase I; i.v., intravenous; OTC, ornithine transcarbamylase; UCD, urea cycle disorder.
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severe encephalopathy and/or seizure, with consistent
EEG findings, treatment with ammonia-scavenging
agents (as recommended in Boxes 1 and 2) should be
initiated. After 2 h, signs of seizures and ammonia levels
should be reassessed; if the patient had an indetermi
nate response to ammonia-scavenging treatment dialysis
should be considered. In patients with serum levels of
ammonia 301–499 μmol/l (513–850 μg/dl) who show
clinical signs of moderate to severe encephalopathy or
seizure, scavenger treatment should be initiated while
the patient is being prepared for dialysis. However, these
numerical values should only serve as a general guide
and should not be applied rigidly. Instead, the evolv
ing clinical status of the patient should be the primary
determinant of whether or not to begin KRT.
Institutional preference and local facilities determine
the choice of dialysis modality. This decision is also influ
enced by the safety, efficacy and complications of each
type of dialysis. Intermittent HD and CKRT have proved
more efficacious than PD15,23. The decision as to whether
to use HD, CKRT or PD should be made jointly by pae
diatric, internal medicine, nephrology, metabolism and
critical care teams, as appropriate. The decision-making
process should take into account the availability of dialy
sis equipment and/or staff, the diagnosis and overall
condition of the patient, the trend in serum ammonia
levels, the response to nitrogen-scavenger therapy and
the age and body weight of the patient.
Peritoneal dialysis guidelines. PD was the primary
treatment for hyperammonaemia before the mid1990s, when HD and CKRT were considered too risky
and challenging to perform in neonates and children.
However, data on the use of PD in this setting show
that this technique has limited efficacy in the treat
ment of hyperammonaemia33, and the use of PD in the
management of hyperammonaemia is now somewhat
controversial.
A study comparing various modalities of KRT in eight
patients with hyperammonaemia showed that PD was
less efficient than intermittent HD or CKRT in reduc
ing ammonia levels34. Improved outcomes were seen in
patients with greater ultrafiltration flow rates; that is,
in those treated with HD and CKRT rather than PD. In
a 1976 case report of a neonate with argininosuccinic
aciduria, PD was initiated on day 4 and resulted in an
improvement in blood ammonia level from 432 μmol/l
(736 μg/dl) to 176 μmol/l (300 μg/dl). However, after
this initial fall in ammonia concentration, PD failed
to lower the blood ammonia concentration any fur
ther35. In a retrospective analysis of data from six Italian
volume 16 | August 2020 | 477
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Box 2 | Recommendations from the consensus panel for NKRT management
• Consensus recommendation 1: immediately conduct further investigations, without delaying treatment, when elevated
ammonia levels are detected (evidence level 4D)
• Consensus recommendation 2: discontinue all oral feeds and provide adequate calories (≥100 kcal/kg daily) as
intravenous glucose and lipids (evidence level 4B)
• Consensus recommendation 3: maintain a glucose infusion rate of 8–10 mg/kg/min and provide lipids (0.5 g/kg daily,
up to 3 g/kg daily) (evidence level 4B)
• Consensus recommendation 4: gradually reintroduce protein (by 0.25 g/kg daily, up to 1.5 g/kg daily) within 48 h
(evidence level 4 C); if stabilization of serum ammonia levels takes longer than 48 h and protein is not supplied, protein
catabolism will drive further ammonia production
• Consensus recommendation 5: use nitrogen-scavenging agents (such as sodium benzoate and sodium phenylacetate)
and urea cycle intermediates (such as l-arginine and l-citrulline) at the recommended dosage (evidence level 4 C)
-- Intravenous sodium benzoate (maximum dose 12 g daily; high-dose benzoate can be toxic and lethal within 1 h):
body weight <20 kg, 250 mg/kg; body weight >20 kg, 5.5 g/m2; given over 90 min as bolus then as maintenance
over 24 h
-- Intravenous sodium phenylacetate: body weight <20 kg, 250 mg/kg; body weight >20 kg, 5.5 g/m2; given over 90 min
as bolus then as maintenance over 24 h
-- Intravenous sodium benzoate and sodium phenylacetate: body weight <20 kg, 250 mg/kg; body weight >20 kg,
5.5 g/m2; given over 90–120 min as bolus then as maintenance over 24 h
-- Intravenous l-arginine hydrochloride: body weight <20 kg, 200 mg/kg for OTC and CPS deficiencies and 600 mg/kg
for ASS and ASL deficiencies; weight >20 kg, 4 g/m2 for OTC and CPS deficiencies and 12 g/m2 for ASS and ASL
deficiencies; given over 90 min as bolus then as maintenance over 24 h
-- Intravenous l-carnitine: 50 mg/kg loading dose given over 90 min, then 100–300 mg/kg daily (not needed for UCD but
needed for organic aciduria)
ASL, argininosuccinate lyase; ASS, argininosuccinate synthase; CPS, carbamoyl phosphate synthase I; NKRT, non-kidney replacement
therapy; OTC, ornithine transcarbamylase; UCD, urea cycle disorder.

centres describing children and neonates with hyper
ammonaemia treated with either PD or HD, intermittent
HD removed ammonia more rapidly than PD, but no
differences were observed in neurological sequelae or
survival between patients who received PD and those
who received HD36. In this study, clinical expertise and
available resources dictated the ammonia level at which
dialysis was initiated and what modality was chosen.
The researchers recommended that PD should be per
formed in situations where extracorporeal therapies are
not available or unsafe and that HD should be performed
in patients who show a rapid rise in blood ammonia
levels36. A PD protocol is provided in Supplementary
Information 3. Box 3 lists recommendations from the
consensus panel for PD.
Some centres, however, might lack the equipment to
enable the use of other extracorporeal therapies and PD
might remain the only treatment option. Although PD
Box 3 | Recommendations from the consensus panel for PD
• Consensus recommendation 6: PD is recommended when other modalities of KRT are
unavailable (evidence level 3B).
• Consensus recommendation 7: rigid peritoneal catheters are not recommended as
they are associated with increased rates of complications such as clotting and
infections (evidence level 3B).
• Consensus recommendation 8: if PD is the only available modality, the consensus
panel recommends its use in the following indications (evidence level 3C):
-- Rapidly deteriorating neurological status, coma, or cerebral oedema
-- Persistently high blood ammonia levels >400 μmol/l (681 μg/dl) refractory to NKRT
medical measures
-- Rapid rise in ammonia levels >300 μmol/l (511 μg/dl) within a few hours that cannot
be controlled via NKRT medical measures
KRT, kidney replacement therapy; NKRT, non-kidney replacement therapy; PD, peritoneal dialysis.

478 | August 2020 | volume 16

offers a quick alternative for the immediate management
of hyperammonaemia if HD or CKRT are not available37,
complications of PD include obstruction and leakage of
the catheters, which can result in delayed toxin clear
ance and increased duration of dialysis38. Additionally,
few devices for PD are suitable for the treatment of
hyperammonaemia in small children. These devices are
not always promptly commercially available, and their
availability mainly depends on the local economic con
text and established practices. In turn, device availability
is a factor that contributes to determining the expertise
of local operators.
CKRT guidelines. The introduction of CKRT (which
includes CVVH and CVVHDF) led to improvements
in the outcomes of patients with hyperammonaemia.
Compared with HD, CKRT results in fewer cardio
vascular complications, less need for plasma and
blood transfusions, and a lower risk of rebound hyper
ammonaemia34,36,39. Owing to its continuous nature,
CKRT is not associated with major fluid or osmotic
shifts and therefore has a reduced likelihood of aggra
vating the raised intracranial pressure associated with
hyperammonaemia40. The need to obtain vascular access
is the main limitation to the use of CKRT.
Continuous venovenous HD (CVVHD) is superior to
conventional HD and PD in infants owing to its ability
to maintain haemodynamic stability by removing iso
tonic fluid40. All forms of CKRT are safe and efficacious
methods for the management of hyperammonaemia;
however, CVVHD enables a higher ammonia clear
ance rate than CVVH. A case report described two
severely symptomatic neonates, aged 5 days and 6 days,
with blood ammonia levels of 881 μmol/l (1,500 μg/dl)
www.nature.com/nrneph
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and 776 μmol/l (1,322 μg/dl), respectively, who were
later diagnosed with OTC deficiency41. Both patients
were admitted to the neonatal intensive care unit. The
5-day-old patient presented with cyanosis and gasp
ing and was intubated and started on CKRT, given his
haemodynamic instability. The ammonia level of the
patient decreased to 367  μmol/l (625 μg/dl) within 2 h
and he exhibited spontaneous movement and neuro
logical improvement within 1 h of starting CKRT41. The
6-day-old patient presented with poor feeding, vomit
ing and somnolence, and was treated with high-dose
CKRT in view of a pretreatment blood ammonia level of
1,387 μmol/l (2,362 μg/dl). The patient’s ammonia levels
decreased dramatically to 90 μmol/l (153 μg/dl) within
7 h of treatment, rebounded to 402 μmol/l (685 μg/dl)
within 10 h, but remained <100 μmol/l (170 μg/dl) over
the next 24 h without further KRT. After 6 months, this
patient underwent liver transplantation41. These case
reports show that CVVHD results in greater ammonia
clearance than CVVH. In neonates undergoing CKRT,
the use of a warmed dialysate provides added haemo
dynamic stability42. Although fewer complications are
associated with CKRT than with other forms of dialysis,
the pre-CKRT status of each individual is a major deter
minant of survival. A retrospective study showed that
the most important prognostic factor was the duration of
hyperammonaemic coma prior to the start of dialysis27;
by contrast, patient outcomes were not influenced by the
rate of ammonia clearance36.
In patients with blood ammonia levels >1,500 μmol/l
(2,555 μg/dl), high-dose CKRT (maximal blood flow rate
Box 4 | Recommendations from the consensus panel for CKRT
• Consensus recommendation 9: CKRT, specifically high-dose CVVHD, is the
recommended first-line treatment for hyperammonaemia when possible (evidence
level 3B).
• Consensus recommendation 10: CKRT should be initiated in a patient with
hyperammonaemia in the following situations:
-- Rapidly deteriorating neurological status, coma, or cerebral oedema with blood
ammonia level >150 μmol/l (256 μg/dl) (evidence level 3B)
-- Presence of either moderate or severe encephalopathy (evidence level 3B).
Moderate encephalopathy is defined as lethargy, distal flexion, decreased activity,
complete extension, hypotonia, weak suck or incomplete Moro reflex, constricted
pupils or bradycardia69. Severe encephalopathy is defined as stupor or coma, no
activity, decerebrate posture, flaccid tone, absent suck, absent Moro reflex, pupils
non-reactive to light, variable heart rate or sleep apnoea69.
-- Persistently high blood ammonia levels >400 μmol/l (681 μg/dl) refractory to NKRT
medical measures (evidence level 3B)
-- Rapid rise in blood ammonia levels to >300 μmol/l (511 μg/dl) within a few hours that
cannot be controlled via NKRT medical therapies (evidence level 3B)
• Consensus recommendation 11: warming the dialysate helps maintain haemodynamic
stability in patients who receive CKRT (evidence level 3B).
• Consensus recommendation 12: high-dose CKRT with Qb 30–50 ml/min, aiming at
Qd/Qb >1.5, may be used for the initial treatment of patients with a blood ammonia
level >1,000 μmol/l (1,703 μg/dl) (evidence level 4D).
• Consensus recommendation 13: step-down CKRT can follow HD or high-dose CKRT
when the blood ammonia level is <200 μmol/l (341 μg/dl) on at least two once-hourly
measurements, keeping in mind that therapy with nitrogen-scavenging agents might
be sufficient to prevent rebound hyperammonaemia (evidence level 4D).
CKRT, continuous kidney replacement therapy; CVVHD, continuous venovenous haemodialysis;
HD, haemodialysis; NKRT, non-kidney replacement therapy; Qb, blood flow rate; Qd, dialysis
fluid flow rate.
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(Qb) 30–50 ml/min; dialysate flow rate (Qd)/Qb >1.5)
can be initiated, which enables rapid clearance of ammo
nia and reduces the need to switch between HD and
CKRT modalities. Experimental and clinical evidence
indicates that a Qd >1,000 ml/h is required to exploit the
maximum potential of CKRT in neonates38. Although
rebound hyperammonaemia has also been reported with
high-dose CKRT, this complication occurs to a lesser
extent than in HD and does not require further KRT
management. Furthermore, CKRT can be completed
in a single dialysis run without the need for a change in
equipment. In two patients with OTC deficiency, rapid
removal of ammonia was seen after initiation of highdose CKRT — Qb 10–20 ml/min in neonates and
infants or, in older children, the maximum blood flow
allowed by the catheter. This high-dose CKRT resulted
in clearance rates (that is, total replacement and/or
Qd) of up to 8,000 ml/1.73 m2/h or more and was safe
for the patients34. In other studies, Qb 10–20 ml/min in
neonates and infants has achieved clearance rates (total
replacement and/or Qd) of ≥2,500 ml/1.73 m2/h41,43.
However, not all CKRT machines can achieve an opti
mal Qd value. One CKRT device (Asahi Sigma Plasauto)
allows a Qd of up to 6 l/h, whereas the Prismaflex and
Fresenius devices (paediatric circuits) limit Qd to 1 l/h.
Overall, these Qd restrictions limit the efficiency of
CKRT and create the need for additional HD in patients
with very high ammonia levels. Additionally, the liter
ature shows that problems with vascular access, hep
arinization, electrolyte alterations and clotting of the
membrane and/or circuit may lead to inadequate CKRT
(that is, delivered other than as prescribed in the recom
mendations below). Protocols for CKRT and high-dose
CKRT are included in Supplementary Information 3.
Recommendations from the consensus panel for CKRT
are presented in Box 4.
Haemodialysis guidelines. Intermittent HD can decrease
blood ammonia concentrations by 75% within 3–4 h
(ref.37). The main limitations of this method in neonates
are the risk of rebound hyperammonaemia and the
need to obtain vascular access, although such access has
been achieved with the use of a peripheral artery and
umbilical vein44. A 2007 study comparing different
forms of KRT in eight infants with hyperammonaemia
found that patients receiving intermittent HD showed a
50% reduction in ammonia levels after 1–2 h, whereas
patients treated with CVVHD took 2–14 h to show this
level of reduction34. However, the presence of rebound
hyperammonaemia often necessitates treatment with
multiple HD sessions, which can cause hypotension
and rapid osmotic shifts that further compromise the
haemodynamic stability of the patient44. The hypoten
sion associated with the use of intermittent HD can
also worsen cerebral oedema and increase the chance of
cerebral herniation in patients with raised intracranial
pressure45. However, in low-body-weight infants, short-
duration, intermittent HD is a safe and effective way to
ensure rapid reversal of hyperammonaemia and enable
the patient to recover between dialysis sessions, which
prevents HD-related prolonged hypotension, membrane
clotting and prolonged heparinization46. The rapid shifts
volume 16 | August 2020 | 479
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Box 5 | Recommendations from the consensus panel for HD
• Consensus recommendation 14: intermittent HD is recommended in patients who
require rapid ammonia clearance (evidence level 3B).
• Consensus recommendation 15: for hyperammonaemia, initiation of intermittent HD
is recommended in the following situations:
-- Rapidly deteriorating neurological status, coma, or cerebral oedema (evidence
level 3B)
-- HD or high-dose CKRT may be used as initial therapy in patients with blood
ammonia levels >1,000 μmol/l (1,703 μg/dl) (evidence level 4D).
CKRT, continuous kidney replacement therapy; HD, haemodialysis.

in osmolarity associated with HD also increase the risk
of further elevations in intracranial pressure, especially
in neonates. Thus, in these patients, osmolarity should
be monitored regularly during HD, and the dialysate for
mula should be modified to minimize or avoid any rapid
shifts in osmolarity47.
In patients with inborn errors of metabolism, high
HD infusion rates enable the administration of calo
ries (along with ammonia clearance) to prevent catab
olism41,48. An HD protocol is listed in Supplementary
Information 3. Box 5 presents recommendations from
the consensus panel for HD.
Hybrid therapy guidelines. The use of HD or CKRT
alone is effective in treating and reducing toxic ammo
nia levels. However, combinations of HD and CKRT,
known as hybrid or sequential therapy, can gradually
reduce ammonia levels while controlling the rebound
effect. The results of a retrospective study showed that
HD should be the first-line KRT modality for rapidly
reducing ammonia levels, followed by CKRT to pre
vent any rebound49. Another advantage of CKRT is the
ability to safely replace electrolytes lost during dialysis,
which is not possible in intermittent HD. Accordingly,
hybrid therapy is initiated with HD when ammonia
Box 6 | Recommendations from the consensus panel for hybrid therapy
• Consensus recommendation 16: HD or CKRT combined with ECMO is recommended
in neonates, especially those who are haemodynamically unstable. The combination
of HD or CKRT with ECMO increases the patient’s blood volume, enables the use of
a larger cannula and facilitates improved haemodynamic control (evidence level 4D).
• Consensus recommendation 17: HD or CKRT combined with ECMO is suggested for
the treatment of hyperammonaemia in the following situations:
-- Haemodynamic instability in a small neonate with poor vascular access for standard
CKRT (evidence level 4D)
-- Rapidly deteriorating neurological status, coma, or cerebral oedema (evidence
level 4D)
-- Presence of moderate or severe encephalopathy. Moderate encephalopathy is
defined as lethargy, distal flexion, decreased activity, complete extension, hypotonia,
weak suck or incomplete Moro reflex, constricted pupils, or bradycardia69. Severe
encephalopathy is defined as stupor or coma, no activity, decerebrate posture,
flaccid tone, absent suck, absent Moro reflex, pupils non-reactive to light, variable
heart rate or sleep apnoea69 (evidence level 4D).
-- Persistently high blood ammonia levels >400 μmol/l (681 μg/dl) refractory to NKRT
medical measures (evidence level 4D)
-- A rapid rise in ammonia levels to >300 μmol/l (511 μg/dl) within a few hours that
cannot be controlled via NKRT medical therapies (evidence level 4D)
CKRT, continuous kidney replacement therapy; ECMO, extracorporeal membrane oxygenation;
HD, haemodialysis; NKRT, non-kidney replacement therapy.
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levels are >1,500 μmol/l (2,555 μg/dl), then transitioned
to CKRT1,41. Step-down CKRT can follow either HD or
high-dose CKRT once ammonia levels are <200 μmol/l
(280 μg/dl) on at least two consecutive hourly measure
ments. Nitrogen-scavenging agents should be instituted
once the patient is off HD or high-dose CKRT to prevent
rebound.
Another hybrid method of KRT is CKRT with ECMO
support. In a neonate requiring urgent dialysis, the need
for a small catheter size and the small volume of the
dialysate circuit can limit ammonia clearance. ECMO is
primarily used in patients with cardiorespiratory failure,
although a few studies have shown the need for ECMO
in low-birth-weight neonates with hyperammonaemia
and severe hypotension requiring HD50–52. The use of
CKRT with ECMO can increase the blood volume of the
patient, enables the use of a larger cannula, avoids haemo
dynamic instability and leads to the rapid clearance of
ammonia. ECMO-assisted CVVHD results in improved
haemodynamic stability and safer dialysis in neonates,
but carries an increased risk of causing a substantial cer
ebrovascular event. This risk is particularly elevated in
low-birth-weight neonates, possibly owing to poor heart
function, increased cerebral blood flow and increased
intracranial pressure53,54.
An alternative form of hybrid therapy consists of
therapeutic hypothermia combined with various KRT
modalities. This approach is based on the recognition
that whole-b ody therapeutic hypothermia can slow
down ammonia production by decreasing metabolism
throughout the body. Each 1 °C decrease in body tem
perature reduces the basal metabolic rate by 8%54. A pilot
study testing various approaches to KRT combined
with therapeutic hypothermia showed a faster decline
and earlier stabilization of ammonia levels when the
same KRT modality was compared in therapeutically
cooled versus normothermic patients55. Further studies
are required to determine the true effects of therapeutic
cooling on the reduction of ammonia levels and the
improvement in neurological outcomes in patients with
hyperammonaemia. Box 6 presents recommendations
from the consensus panel for hybrid therapy.

Conclusions
A high index of suspicion for hyperammonaemia is
mandatory in paediatric patients of any age with sugges
tive clinical symptoms, given that almost all survivors
have developmental disabilities that correlate with the
number, severity and duration of hyperammonaemic
episodes. Prompt treatment with KRT and/or NKRT,
the choice of which depends on the ammonia con
centrations and presenting symptoms of the patient,
is crucial. The paediatric literature with regard to
hyperammonaemia requiring KRT is limited. To our
knowledge, a consensus recommendation including
a literature review with expert guideline recommen
dations has not yet been published. More studies are
needed to strengthen the recommendations presented
in this article; these recommendations will be followed
by an audit.
Published online 8 April 2020
www.nature.com/nrneph
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